Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms. Issue 12 (16th November 2016)

• Record Type: Journal Article
• Authors: Xia, Daniel; Hasserjian, Robert P.
• Is Part Of: American journal of hematology. Volume 91:Issue 12(2016:Dec.)
• Page Start: 1277
• Page End: 1280
• Publication Date: 2016-11-16
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24578
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract : Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are myeloproliferative neoplasms characterized by recurrent somatic mutations in JAK2, CALR, and MPL . This short review addresses (1) the spectrum of mutations seen in PV, ET, and PMF, (2) the emerging genotype‐phenotype correlations, (3) the current role of molecular testing in disease classification and management, and (4) several important considerations for selecting an appropriate molecular test. In our view, sequential testing algorithms and simultaneous assessment of multiple mutations by next‐generation sequencing are both valid approaches to testing. Am. J. Hematol. 91:1277–1280, 2016. © 2016 Wiley Periodicals, Inc.